Clinical trials: ctDNA
Upper Urinary Tract Urothelial Carcinoma
Neoadjuvant Nivolumab for Upper Tract Urothelial Carcinoma
The aim of this study is to explore efficacy and safety of neoadjuvant nivolumab for non-metastatic upper tract urothelial carcinoma (UTUC), and explore the potential predictive biomarkers of immunotherapy.
- Trial name
- NCT05160285
- Testing
- Nivolumab 100 MG in 10 ML Injection
- Where
- Taiwan
- Volunteers
- 29 people
- Sponsor
- YULISU
Pancreatic Adenocarcinoma, Pancreatic Cysts
Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors
This multicenter randomized trial aims to primarily assess and compare the functional recovery of patients who undergo open versus robotic pancreaticoduodenectomy for benign and malignant lesions of the head of the pancreas.
- Conditions
- Pancreatic Adenocarcinoma, Pancreatic Cysts, Pancreatic Endocrine Tumors, Chronic Pancreatitis
- Trial name
- PORTAL (NCT04400357)
- Testing
- Robotic pancreaticoduodenectomy, Open pancreaticoduodenectomy
- Where
- China
- Volunteers
- 268 people
- Sponsor
- Ruijin Hospital
Diffuse Large B Cell Lymphoma (DLBCL)
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)
This is a phase ll study of participants with untreated diffuse large B Cell lymphoma (DLBCL).
- Trial name
- GRAIL (NCT06050694)
- Testing
- glofitamab
- Where
- 3 sites in Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Melanoma, Skin Cancer
Circulating Tumor DNA in Melanoma Patients
The aim of this prospective clinical study is to determine whether the presence and quantity of circulating tumor DNA (ctDNA) can serve as a predictive factor for recurrence or progression of melanoma.
- Trial name
- ctDNA (NCT07422805)
- Testing
- Blood Sampling for ctDNA Analysis
- Where
- Slovenia
- Volunteers
- 176 people
- Sponsor
- Institute of Oncology Ljubljana
Carcinoma, Non-Small-Cell Lung
ctDNA Guided Treatment of Early Resistance to Targeted Treatment
The current strategy is to test for treatment resistance at the time of radiological progression and design subsequent treatment based on the mechanism of resistance.
- Trial name
- TATIN (NCT04148066)
- Testing
- ctDNA blood sample
- Where
- 2 sites in Netherlands
- Volunteers
- 104 people
- Sponsor
- The Netherlands Cancer Institute
Glioblastoma
Radiogenomics in Glioblastoma: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers
The purpose of this study is to evaluate relationships between multiparametric imaging biomarkers and genetic analysis in glioblastoma patients.
- Trial name
- NCT05541042
- Testing
- Observational only
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Henan Provincial People's Hospital
Hepatocellular Carcinoma
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA
The goal of the REMNANT study is to confirm the clinical value of detecting a new biomarker, ctDNA (circulating tumor DNA), in the follow-up of patients with operated liver cancer.
- Trial name
- REMNANT (NCT05375370)
- Testing
- circulating tumor DNA dosage
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Rouen
Lung Neoplasms
Practical Usability of EGFR Mutation Detection in ctDNA From Resectable NSCLC
The aim of the study is to assess the practical usability of EGFR mutation detection in ctDNA from early NSCLC.
- Trial name
- NCT04922073
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Samsung Medical Center
HPV-Related Carcinoma, Uterine Cervical Cancer
Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes
After definitive radiotherapy (RT) treatment (with or without chemotherapy), cervical and anal canal neoplasms frequently exhibit disease persistence or recurrence.
- Conditions
- HPV-Related Carcinoma, Uterine Cervical Cancer, Anal Canal Cancer, HPV-Related Anal Squamous Cell Carcinoma
- Trial name
- ANA (NCT06640283)
- Testing
- ctDNA test, Pembrolizumab
- Where
- Brazil
- Volunteers
- 150 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA)
TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort
Purpose of the Study: Bile duct cancers are rare and aggressive. About 250 new cases are diagnosed each year in Denmark. These cancers are difficult to detect early, so only about 20% of patients can have surgery when diagnosed.
- Conditions
- Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA), Gall Bladder Cancer, Biliary Tract Cancers (BTC)
- Trial name
- TRACE-BTC (NCT07454486)
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Aarhus University Hospital
Squamous Cell Carcinoma of Head and Neck
Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck
This study will test the ability of a personalized blood test to determine which head and neck cancer patients will have a recurrence after treatment.
- Trial name
- MRD-DUCHESS (NCT06744296)
- Testing
- Blood Draws and Tissue Sample(s)
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Cancer, Lung, Cancer, Breast
Early Detection of Five Common Cancers Using the ctDNA Analysing Test
This is a multi-centre, prospective cohort study, aiming to evaluate a blood test in early detection of the four common cancers, based on the investigation of the circulating tumour DNA (ctDNA).
- Conditions
- Cancer, Lung, Cancer, Breast, Cancer Liver, Cancer, Colorectal
- Trial name
- K-DETEK (NCT05227261)
- Where
- Vietnam
- Volunteers
- 9,057 people, healthy volunteers welcome
- Sponsor
- Gene Solutions
Colorectal Cancer
Influence of the Surgical Technique Used for Colectomies on the Concentration of Circulating Tumor DNA and the Presence of Circulating Tumor Cells: Comparison of the "no Touch" Technic With Either First Clamping of the Mesenteric Vessels or First Mobilization of the Tumor Followed by Clamping.
Colectomy is the most commonly used therapeutic approach for the treatment of non-metastatic colorectal cancer. This approach is generally very effective however the rate of recurrence and the appearance of metachronous…
- Trial name
- ADNCHIR (NCT03809403)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cancer Colorectal
ctDNA Methylation Application in Postoperative Relapse and Adjuvant Chemotherapy Efficacy Evaluation
In this study, the investigators aimed to apply their previously developed multi-locus blood-based assay targeting circulating tumor DNA methylation to monitor postoperative relapse and evaluate adjuvant chemotherapy efficacy in…
- Trial name
- NCT05536089
- Testing
- a multi-locus blood-based assay
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Singlera Genomics Inc.
Breast Cancer
Circulating Tumor DNA After Neoadjuvant Chemotherapy
Trial assessing the prognostic value of ctDNA mutations from samples taken sequentially in patients with invasive breast cancer initially treated with neoadjuvant chemotherapy and whose tumor is not in complete histological…
- Trial name
- ALIENOR (NCT03357120)
- Testing
- Follow-up after neoadjuvant chemotherapy
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Institut Bergonié
Peritoneal Carcinomatosis
Bonds Between Circulating Tumoral ADN (ctDNA) and the Development of Peritoneal Carcinomatosis for Patients Under PIPAC
PIPADN is a pilot monocentric, study with a total duration of 42 months. The purpose of this study is to describe the variation of plasma ctDNA concentration between the 1st and the 3rd PIPAC session in patients with peritoneal…
- Trial name
- PIPADN (NCT04766502)
- Testing
- Blood sample (20 ml) and EORTC QLQC30 survey
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Institut de Cancérologie de Lorraine
Pancreatic Neoplasm, Pancreas Cancer
MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer
Developing a characteristic ctDNA methylation panel for pancreatic ductal adenocarcinoma and establishing an intelligent diagnostic and dynamic monitoring model based on ctDNA methylation.
- Trial name
- NCT07045571
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Yingbin Liu, MD, PhD, FACS
Lung Cancer
T790M Plasma Testing Methodology Comparison and Clinical Validation
The aim of this study is to evaluate concordance of T790M mutation plasma testing between the Cobas test and each of other platforms: Super-ARMS, digital PCR or NGS.
- Trial name
- ADELOS (NCT02997501)
- Testing
- T790M+ Testing, Baseline Visit Blood & Urine Testing, Baseline ECG
- Where
- 7 sites in China
- Volunteers
- 256 people
- Sponsor
- AstraZeneca
Uveal Melanoma
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker.
- Trial name
- NCT06070012
- Testing
- Tebentafusp
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Diwakar Davar
Plasma EGFR Mutation-positive Lung Cancer
Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer
this single arm，open-label，multi-center study is aimed to evaluate the efficiency of icotinib in plasma ctDNA EGFR mutation-positive patients diagnosed with lung cancer
- Trial name
- CHALLENGE (NCT03346811)
- Testing
- Icotinib
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.